Clinical trials: Resectable Esophageal Cancer
Immunotherapy;Envafolimab; Esophageal Cancer
Envafolimab Combined With Abraxane and Cisplatinas as Neoadjuvant Treatment for Resectable Esophageal Cancer
Big breakthroughs have been made in the combination therapy of immune checkpoint inhibitors when it comes to the neoadjuvant therapy of esophageal cancer.
- Trial name
- NCT05828381
- Testing
- Envafolimab, Abraxane, Cisplatin
- Volunteers
- 33 people
- Sponsor
- Fujian Medical University Union Hospital
Advanced Esophageal Squamous Cell Cancer
Tislelizumab Combined With Neoadjuvant Radiotherapy and Chemotherapy for Resectable Esophageal Squamous Cell Carcinoma.
This study aimed to evaluate the safety and feasibility of neoadjuvant tislelizumab combined with chemoradiotherapy in patients with resectable esophageal squamous cell cancer.
- Trial name
- NCT05323890
- Testing
- Tislelizumab Combined With Neoadjuvant Radiotherapy and Chemotherapy
- Where
- China
- Volunteers
- 15 people
- Sponsor
- Shandong Cancer Hospital and Institute
Sintilimab and Anlotinib in Combination With Chemotherapy
Sintilimab and Anlotinib Combined With Chemotherapy in Neoadjuvant Treatment of Resectable Esophageal Cancer
The study focused on patients with T2-4NxM0 resectable esophageal carcinoma. Neoadjuvant treatment involved administering anlotinib (10 mg orally, once a day, 2 weeks on and 1 week off) for anti-angiogenesis and sintilimab (200…
- Trial name
- NCT06015035
- Testing
- Sintilimab and anlotinib in combination with chemotherapy
- Where
- 2 sites in China
- Volunteers
- 17 people
- Sponsor
- Tang-Du Hospital
Esophageal Squamous Cell Carcinoma
Efficacy and Safety of TPF Induction Chemotherapy for Borderline-resectable Esophageal Squamous Cell Carcinoma
This trial studies the efficacy and safty of paclitaxel in combination with cisplatin and 5-fluorouracil(TPF) induction chemotherapy for locally advanced borderline-resectable esophageal squamous cell carcinoma.
- Trial name
- NCT02976909
- Testing
- Paclitaxel+Cisplatin+5fluorouracil
- Where
- China
- Volunteers
- 46 people
- Sponsor
- Yuhong Li
Esophageal Squamous Cell Carcinoma
Neoadjuvant Chemotherapy Versus Neoadjuvant Chemoradiotherapy for Resectable Locally Advanced Esophageal Cancer (HCHTOG1903)
Multimodal treatment combining surgery with chemotherapy and/or radiotherapy is necessary to improve the chances of survival in patients with locally advanced thoracic esophageal cancer.
- Trial name
- HCHTOG1903 (NCT04138212)
- Testing
- Paclitaxel, Cisplatin, neoadjuvant chemoradiation therapy
- Where
- China
- Volunteers
- 456 people
- Sponsor
- Henan Cancer Hospital
Esophageal Squamous Cell Carcinoma
Active Surveillance After Neoadjuvant Adebrelimab Combined With Chemoradiotherapy for Resectable ESCC
In this prospective trial, patients demonstrating clinical complete response (cCR) as determined by a standard response assessment protocol (incorporating clinical and molecular diagnostic methods) will be offered organ-sparing…
- Trial name
- NCT06861894
- Testing
- Adebrelimab and nab-paclitaxel and carboplatin, Radiation, standard oesophagectomy
- Where
- China
- Volunteers
- 164 people
- Sponsor
- Zhigang Li
Gastric-Esophageal Cancer
Signatera-Guided De-escalation of Adjuvant Therapy in Resectable Stage II-IVa Gastric/Gastric-Esophageal Cancer
The goal of this clinical trial is to assess if circulating tumor DNA, as assessed by Signatera tumor-informed MRD assay, can guide de-escalation of adjuvant therapy in patients with resectable Stage II-IVa…
- Trial name
- SIGNAL GEC-101 (NCT07565857)
- Testing
- Signatera Genome ultra-sensitive ctDNA blood test
- Volunteers
- 1,000 people
- Sponsor
- Natera, Inc.
Esophageal Squamous Cell Carcinoma
BTLA Inhibitor (JS004) Combined with Toripalimab and Chemotherapy in the Perioperative Treatment of Resectable Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma
This is a single-center, single-arm, phase II study, aiming to preliminarily explore the efficacy and safety of JS004 combined with toripalimab and chemotherapy for perioperative treatment of locally advanced thoracic esophageal…
- Trial name
- NCT06588335
- Testing
- BTLA inhibitor (JS004), Toripalimab, Paclitaxel, Cisplatin
- Volunteers
- 20 people
- Sponsor
- Henan Provincial People's Hospital
Esophageal Carcinoma
Feasibility Study of Chemoradiation, TRAstuzumab and Pertuzumab in Resectable HER2+ Esophageal Carcinoma
Despite neoadjuvant chemoradiation regimens esophageal cancer remains a disease with poor outcome. The clinical benefit of HER2 targeting with trastuzumab has been shown in the setting of advanced disease and disease and safety…
- Trial name
- TRAP (NCT02120911)
- Testing
- Pertuzumab, trastuzumab
- Where
- Netherlands
- Volunteers
- 40 people
- Sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Esophageal Cancer
Feasibility Study of Adjuvant Treatment With S-1 and Oxaliplatin in Patients With Resectable Esophageal Cancer
In this prospective single arm study the investigators will assess the feasibility of S-1 and Oxaliplatin as adjuvant treatment in patients with esophageal cancer.
- Trial name
- SOX (NCT02347904)
- Testing
- S-1 and Oxaliplatin
- Where
- Netherlands
- Volunteers
- 40 people
- Sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Carcinoma, Squamous Cell, Oral Cancer
Carboplatin, Nab-Paclitaxel, Durvalumab Before Surgery and Adjuvant Therapy in Head and Neck Squamous Cell Carcinoma
Participants in this study have a type of cancer called squamous cell carcinoma of the head and neck (SCCHN). Their SCCHN has spread around the area where the cancer first started. This is called locally-advanced SCCHN.
- Conditions
- Carcinoma, Squamous Cell, Oral Cancer, Oropharynx Cancer, Larynx Cancer
- Trial name
- NCT03174275
- Testing
- Durvalumab, Carboplatin, Nab-paclitaxel
- Where
- 2 sites in United States
- Volunteers
- 39 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Esophageal Squamous Cell Carcinoma, Neoadjuvant Therapy
Efficacy and Safety of Neoadjuvant Envafolimab Combined With Albumin-bound Paclitaxel and Carboplatin for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma
This single center, prospective, single arm clinical study aims to evaluate the clinical efficacy and safety of Envafolimab combined with albumin bound paclitaxel and carboplatin as neoadjuvant therapy for locally advanced…
- Trial name
- NCT07266493
- Testing
- Chemotherapy （Albumin bound paclitaxel and Carboplatin）
- Where
- China
- Volunteers
- 26 people
- Sponsor
- Shanghai Zhongshan Hospital
Esophageal Cancer
Neoadjuvant Docetaxel and Cisplatin Plus Chemoradiotherapy Followed By Surgery in Treating Patients With Locally Advanced, Resectable Esophageal Cancer
RATIONALE: Drugs used in chemotherapy, such as docetaxel and cisplatin, use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00072033
- Testing
- Cisplatin and Docetaxel
- Where
- 9 sites in Switzerland
- Volunteers
- 66 people
- Sponsor
- Swiss Cancer Institute
Cancer of the Esophagus
Phase I/II Study of Panitumumab, Capecitabine and Oxaliplatin w EBRT for Esophageal Cancer
The primary purpose of this trial is to define the maximum tolerated and/or recommended phase II dose of the combination of panitumumab, oxaliplatin and capecitabine in patients undergoing radiation therapy for carcinoma of the…
- Trial name
- POXX (NCT00578071)
- Testing
- Panitumumab, Capecitabine, Oxaliplatin
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- Brian Czito
Esophageal Squamous Cell Carcinoma, Neoadjuvant Therapy
Carrelizumab, Chemotherapy and Apatinib in the Neoadjuvant Treatment of Resectable Esophageal Squamous Cell Carcinoma
China with high incidence of esophageal cancer, the number of new cases and deaths account for about 50% of the world every year.
- Trial name
- NCT04666090
- Testing
- Carillizumab, Esophagectomy, Samples
- Where
- China
- Volunteers
- 42 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Anaplastic Astrocytoma, Anaplastic Oligoastrocytoma
Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors
This phase I trial studies the side effects and best schedule of vaccine therapy with or without sirolimus in treating patients with cancer-testis antigen (NY-ESO-1) expressing solid tumors.
- Conditions
- Anaplastic Astrocytoma, Anaplastic Oligoastrocytoma, Anaplastic Oligodendroglioma, Estrogen Receptor Negative
- Trial name
- NCT01522820
- Testing
- DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Laboratory Biomarker Analysis, Pharmacological Study
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Roswell Park Cancer Institute
Cervical Esophageal Cancer
Surgery or Chemoradiotherapy for Cervical Esophageal Cancer
To compare surgery with definitive chemoradiotherapy for patients with resectable cervical esophageal squamous cell carcinoma.
- Trial name
- NCT05327517
- Testing
- Esophagectomy
- Where
- China
- Volunteers
- 192 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Esophageal Adenocarcinoma, Esophageal Squamous Cell Carcinoma
A Phase II Trial to Evaluate the Effect of Itraconazole on Pathologic Complete Response Rates in Resectable Esophageal Cancer
Esophageal cancer, which has a low 5-year overall survival rate (<20%) is increasing in incidence. Previous studies have shown that Hedgehog, AKT, and angiogenic signaling pathways are activated in a significant number of…
- Conditions
- Esophageal Adenocarcinoma, Esophageal Squamous Cell Carcinoma, Gastroesophageal Junction Carcinoma
- Trial name
- NCT05563766
- Testing
- Itraconazole
- Where
- 7 sites in United States
- Volunteers
- 78 people
- Sponsor
- VA Office of Research and Development
Esophageal Cancer
Surgery With or Without Radiation Therapy and Chemotherapy in Treating Patients With Esophageal Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Giving combination chemotherapy with radiation therapy before surgery may shrink the tumor so it can be…
- Trial name
- NCT00047112
- Testing
- cisplatin, fluorouracil, conventional surgery
- Where
- 73 sites in Belgium, France and 2 more
- Volunteers
- 195 people
- Sponsor
- Federation Francophone de Cancerologie Digestive
Esophageal Cancer
Combination Chemotherapy in Treating Patients With Esophageal Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00041262
- Testing
- cisplatin, epirubicin hydrochloride, fluorouracil
- Where
- United Kingdom
- Volunteers
- 1,300 people
- Sponsor
- Medical Research Council